Indeed, they devised a dual CAR-expressing construct that combined CD19- and CD123-mediated T-cell activation and demonstrated that it provides superior in vivo activity against B-ALL cells compared to single-expressing CARs or pooled CAR T cells. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.